Circumvent Pharmaceuticals was founded with the mission to develop precision medicines for neurodegenerative diseases, addressing a significant unmet need in this area. The company focuses on heritable forms of neurodegeneration to facilitate drug discovery and development for both rare and common neurodegenerative conditions. Their initial target is Batten Disease, a rare and fatal disorder, with plans to expand their research and treatment options to other neurodegenerative diseases.

Notable affiliated individuals and investors include experts in the field of neurodegenerative research and prominent venture capital firms specializing in biotech innovations. Circumvent has achieved significant milestones in preclinical trials, showcasing promising results that have garnered attention within the scientific community. Their impact lies in pioneering new treatment pathways that could potentially alter the course of neurodegenerative diseases, offering hope to patients and families affected by these debilitating conditions.